ReviewPharmaceuticals (Basel, Switzerland)2026
A Comprehensive Review on Irinotecan-Induced Delayed Diarrhea: From Mechanisms to Therapeutic Options.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irinotecan is a first-line medication for metastatic colorectal cancer. It is known that irinotecan-induced delayed diarrhea is closely related to metabolic processes in the human body. In particular, the synergies of multiple metabolic enzymes/transporters mediate the transport/regeneration of intestinal SN38. This efficient metabolite derived from irinotecan not only exerts robust cytotoxic effects, but also extends contact duration with the intestinal wall during enterohepatic circulation. These factors further affect the intestinal microenvironment, including intestinal flora disorder, intestinal immune dysregulation, and intestinal barrier impairment, which ultimately causes the occurrence of delayed diarrhea. At present, dose adjustment of irinotecan and combining drugs are common measures for clinical use. However, these regimens have shown limited therapeutic efficacy and face the risk of chemotherapy failure. Numerous studies have shown that herbal medicines and derived phytochemicals may also be promising complementary treatments. The characteristics of multi-target regulation of herbs are very suitable for the intervention strategy of complex diseases with multiple pathogenic links. This review focuses on the development of irinotecan-induced delayed diarrhea. We generalized the complex pathogenesis in detail and summarized relevant potential drugs and clinical agents. Special attention was paid to the feasibility of traditional Chinese medicine treatment. This will help expand medication regimens for irinotecan-related diarrhea and provide a reference for the development of precision drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.